Impact of A Nutritional Supplements' Combination (FERTILIS) on Male Infertility (FERTILIS)

Impact of A Nutritional Supplements' Combination (FERTILIS) On Male Infertility: A Monocentric Double Blind Randomized Placebo Controlled Trial

Infertility is a major health problem affecting up to 15% of couples of reproductive age globally. For several years, it was assumed that most reproductive problems could be attributed to the female partner, but research in recent years has demonstrated that males were solely responsible for 20-30% of infertility cases and contributed to 50% of infertility cases overall. The term ''male infertility'' does not constitute a defined clinical syndrome, but rather a collection of different conditions exhibiting a variety of etiologies.

It is far increasingly known that reactive oxygen species (ROS) are of significant pathophysiological importance in the etiology of male infertility. ROS are highly reactive oxidizing agents belonging to the class of free radicals containing one or more unpaired electrons, which are continuously being generated through metabolic and pathophysiologic processes. It has been suggested that oxidants interfere with normal sperm function via membrane lipid peroxidation and fragmentation of nucleic acids, which result in sperm dysfunction. Due to the sperm cell membrane abundance of polyunsaturated fatty acids (PUFAs) and the capacity of sperm to generate ROS, human spermatozoa are highly susceptible to oxidative stress.

Since growing evidence indicates that oxidative stress can be a primary cause of male infertility, non-enzymatic antioxidants play a significant protective role against oxidative damages and lipid peroxidation. In addition, micronutrients and antioxidants are often used with good results in men with idiopathic infertility.

Keeping in view the main protection provided by seminal plasma antioxidants against oxidative damages, a previous study showed that the dietary management with an eight nutritional supplements' combination, similar to this study's product and containing antioxidants, achieved a significant improvement in sperm quality up to a completely normal semen analysis. Also, another study confirmed the hypothesis that the combination of individual nutritional supplements as described in literature showed significantly better results than the sum of the effects of single administration.

Study Overview

• Status: Recruiting
• Conditions: Infertility, Male; Subfertility, Male
• Intervention / Treatment: Dietary supplement: FERTILIS HOMME®; Other: PLACEBO

• Study Type: Interventional
• Enrollment (Anticipated): 300
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Amina Radoui, MSc; Phone Number: 0021698709295; Email: a.radoui@medis.com.tn

Study Locations

• Tunisia
  • Sousse, Tunisia
    • Recruiting
    • Farhat Hached Hospital
    • Contact: Mounir Ajina, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male ≥ 20 years of age
• Attending the Department of Obstetrics and Gynecology of Farhat Hached University Hospital, Sousse, Tunisia, for consultation or semen analysis as part of infertility investigations
• Diagnosis of oligozoospermia (WHO 2010 definition)
• Diagnosis of Asthenozoospermia (WHO 2010 definition)
• Diagnosis of teratozoospermia1 (WHO 2010 definition)
• Diagnosis of idiopathic infertility
• Couple is candidate for Intrauterine Insemination (IUI), In Vitro Fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

• Inclusion visit (prior to treatment initiation): Patients will be selected during this initial visit if they meet all inclusion and none of the exclusion criteria.
• Randomization visit: around 1-week post inclusion visit: Patients will be given either of study interventions.
• Follow up visit 1-month post treatment initiation: Patients will be given study interventions' refill for 1 month.
• Follow up visit 2-months post treatment initiation: Patients will be given study interventions' refill for another month.
• Follow up visit 3-months post treatment initiation: Patients will undergo laboratory assessment.
• Follow up visits every 3-months post Visit: Patients' female partner will undergo laboratory and clinical assessment.
• End of trial (CLOSING) visit 24-months post treatment initiation: Patients' female partner will undergo laboratory and clinical assessment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FERTILIS HOMME® group (group A); Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.	Dietary supplement: FERTILIS HOMME®; L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
Placebo Comparator: Placebo group (group B); Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months	Other: PLACEBO; Sugar pills

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sperm DNA fragmentation Index (DFI)	To evaluate the effect of a nutritional supplement's combination of 8 active compounds (L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg; FERTILIS HOMME®, Les Laboratoires MédiS, Tunisia), on sperm DNA fragmentation index (DFI).	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sperm quantity	Ejaculatory volume (ml) and sperm cell density (mill/ml	3 months
Sperm quality	Sperm morphology and sperm total motility/progressive motility	Up to 3 months
Occurrence of spontaneous pregnancy		Through study completion, an average of 2 years
Occurrence of pregnancy consecutive to Assisted Reproductive Technology (ART)		Through study completion, an average of 2 years
Fertilization rate during in vitro fertilization (IVF)		Up to 3 months
Embryo cleavage rate and embryo quality during intracytoplasmic sperm injection (ICSI)		Up to 3 months
Achievement of clinical pregnancy		Through study completion, an average of 2 years
Achievement of live birth		Through study completion, an average of 2 years
Number of Adverse Events	To assess the safety of the study product	Through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: Les Laboratoires des Médicaments Stériles
• Investigators: Principal Investigator: Mounir Ajina, Dr., Farhat Hached Hospital; Principal Investigator: Latifa Lassoued, Dr., Farhat Hached Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2020
• Primary Completion (Anticipated): December 30, 2021
• Study Completion (Anticipated): December 30, 2022

Study Registration Dates

• First Submitted: December 5, 2019
• First Submitted That Met QC Criteria: December 7, 2019
• First Posted (Actual): December 10, 2019

Study Record Updates

• Last Update Posted (Actual): July 29, 2021
• Last Update Submitted That Met QC Criteria: July 27, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infertility; Infertility, Male
• Other Study ID Numbers: FERTILIS-349

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No